It was tongue in cheek (the $1.50), but rant away. Its hilarious, you get told off by some poster for being at all objective about the lack of insight/data from poor management, and then told off by another for gracious to long-term holders on its prospects. Its almost like posters like you are the problem, and not me....some of the people some of the time....
You are the one being naive, to the historical volatility of REC and mkts at the micro-cap end, if you don't think approval in a country with some 15 million people with Diabetes, some 1-1.5 million of which likely to develop DFU's (let alone the numerous other non-DFU infections) might not possibly send it there again.
I sat on what was a micro-capped bio-tech building to a top 20 holder for years, its share price doing little despite tides of promising fundamentals, approvals and news. It recently suddenly jumped 4 fold in 4 months. No new news. Just the AFR finally recognising that a load of prominent buyers were buying in perhaps the catalyst. Never underestimate mkt volatility - or investor greed and exuberance.
"where's the market?", you say? Um my post showed you exactly where with prevalence rates of DFU's in Indonesia. What a stupid question - seeing as you insist on being brusque.
RCE Price at posting:
43.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)